Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | CRSF 2021-HN-001: assessing the use of metronomic chemotherapy in low-income settings

Rushabh Kiran Kothari, MD, Narayana Multispeciality Hospital, Ahmedabad, India, details the findings of the CRSF 2021-HN-001 trial, which assessed the use of metronomic chemotherapy for head and neck cancer. Median overall survival (OS) was greater and statistically significant. Progression-free survival (PFS) acted as one of the secondary endpoints, and was also statistically significant. Adverse events (AEs) occurred at a lower rate with metronomic chemotherapy. Triple metronomic chemotherapy was shown to have many advantages in terms of improved OS, PFS, and lower rates of AEs in comparison to other standard of care treatments. Additionally, as a complaint treatment, which is prescribed orally, it is easy to administer. This makes metronomic chemotherapy an important consideration for standard of care in less economically developed countries. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.